Literature DB >> 24351928

Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones.

Chunzhang Yang1, Cody L Swallows, Chao Zhang, Jie Lu, Hongbin Xiao, Roscoe O Brady, Zhengping Zhuang.   

Abstract

Gaucher disease is caused by mutations in the glucosidase, beta, acid gene that encodes glucocerebrosidase (GCase). Glucosidase, beta, acid mutations often cause protein misfolding and quantitative loss of GCase. In the present study, we found that celastrol, an herb derivative with known anticancer, anti-inflammatory, and antioxidant activity, significantly increased the quantity and catalytic activity of GCase. Celastrol interfered with the establishment of the heat-shock protein 90/Hsp90 cochaperone Cdc37/Hsp90-Hsp70-organizing protein chaperone complex with mutant GCase and reduced heat-shock protein 90-associated protein degradation. In addition, celastrol modulated the expression of molecular chaperones. Bcl2-associated athanogene 3 and heat shock 70kDa proteins 1A and 1B were significantly increased by celastrol. Furthermore, BAG family molecular chaperone regulator 3 assisted protein folding and maturation of mutant GCase. These findings provide insight into a therapeutic strategy for Gaucher disease and other human disorders that are associated with protein misfolding.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24351928      PMCID: PMC3890874          DOI: 10.1073/pnas.1321341111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation.

Authors:  Gautam Sethi; Kwang Seok Ahn; Manoj K Pandey; Bharat B Aggarwal
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

2.  Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.

Authors:  Wei Zheng; Janak Padia; Daniel J Urban; Ajit Jadhav; Ozlem Goker-Alpan; Anton Simeonov; Ehud Goldin; Douglas Auld; Mary E LaMarca; James Inglese; Christopher P Austin; Ellen Sidransky
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

3.  ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity.

Authors:  Idit Ron; Mia Horowitz
Journal:  Hum Mol Genet       Date:  2005-07-06       Impact factor: 6.150

Review 4.  Enzyme replacement for lysosomal diseases.

Authors:  Roscoe O Brady
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

5.  Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice.

Authors:  Huanjie Yang; Di Chen; Qiuzhi Cindy Cui; Xiao Yuan; Q Ping Dou
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

6.  Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.

Authors:  M J Egorin; D M Rosen; J H Wolff; P S Callery; S M Musser; J L Eiseman
Journal:  Cancer Res       Date:  1998-06-01       Impact factor: 12.701

7.  A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells.

Authors:  Tao Zhang; Adel Hamza; Xianhua Cao; Bing Wang; Shuwen Yu; Chang-Guo Zhan; Duxin Sun
Journal:  Mol Cancer Ther       Date:  2008-01       Impact factor: 6.261

8.  FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

Authors:  Bhupinder S Mann; John R Johnson; Martin H Cohen; Robert Justice; Richard Pazdur
Journal:  Oncologist       Date:  2007-10

9.  Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule.

Authors:  Amy Trott; James D West; Lada Klaić; Sandy D Westerheide; Richard B Silverman; Richard I Morimoto; Kevin A Morano
Journal:  Mol Biol Cell       Date:  2008-01-16       Impact factor: 4.138

Review 10.  Structural and functional diversities between members of the human HSPB, HSPH, HSPA, and DNAJ chaperone families.

Authors:  Michel J Vos; Jurre Hageman; Serena Carra; Harm H Kampinga
Journal:  Biochemistry       Date:  2008-06-17       Impact factor: 3.162

View more
  21 in total

1.  Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation.

Authors:  Chunzhang Yang; Herui Wang; Dongwang Zhu; Christopher S Hong; Pauline Dmitriev; Chao Zhang; Yan Li; Barbara Ikejiri; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-12       Impact factor: 11.205

Review 2.  Genetics and underlying pathology of dementia.

Authors:  Beata Ferencz; Lotte Gerritsen
Journal:  Neuropsychol Rev       Date:  2015-01-08       Impact factor: 7.444

Review 3.  Emptying the stores: lysosomal diseases and therapeutic strategies.

Authors:  Frances M Platt
Journal:  Nat Rev Drug Discov       Date:  2017-11-17       Impact factor: 84.694

4.  Taxodione and arenarone inhibit farnesyl diphosphate synthase by binding to the isopentenyl diphosphate site.

Authors:  Yi-Liang Liu; Steffen Lindert; Wei Zhu; Ke Wang; J Andrew McCammon; Eric Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-09       Impact factor: 11.205

Review 5.  Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease.

Authors:  Caleb Pitcairn; Willayat Yousuf Wani; Joseph R Mazzulli
Journal:  Neurobiol Dis       Date:  2018-03-14       Impact factor: 5.996

6.  Celastrol and Its Role in Controlling Chronic Diseases.

Authors:  Shivaprasad H Venkatesha; Kamal D Moudgil
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

7.  Expanding rare disease drug trials based on shared molecular etiology.

Authors:  Philip J Brooks; Danilo A Tagle; Steve Groft
Journal:  Nat Biotechnol       Date:  2014-06       Impact factor: 54.908

Review 8.  Molecular regulations and therapeutic targets of Gaucher disease.

Authors:  Yuehong Chen; Neetu Sud; Aubryanna Hettinghouse; Chuan-Ju Liu
Journal:  Cytokine Growth Factor Rev       Date:  2018-04-11       Impact factor: 7.638

Review 9.  Lysosomal storage diseases and the heat shock response: convergences and therapeutic opportunities.

Authors:  Linda Ingemann; Thomas Kirkegaard
Journal:  J Lipid Res       Date:  2014-05-16       Impact factor: 5.922

Review 10.  [Hypertrophic chondrocytes: Programmed cell death or stem cell reservoir?].

Authors:  A-C Severmann; A Vortkamp
Journal:  Z Rheumatol       Date:  2015-12       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.